<clinical_study>
<study_id>
<org_name>
  Bayer
</org_name>
<org_full_name>
  Bayer
</org_full_name>
<org_study_id>
  100555
</org_study_id>
<nct_id>
  NCT00101400
</nct_id>
</study_id>
<is_fda_regulated>
  Yes
</is_fda_regulated>
<is_section_801>
  Yes
</is_section_801>
<delayed_posting>
  No
</delayed_posting>
<brief_title>
<textblock>
  BAY43-9006 - Phase II in Advance Breast Cancer
</textblock>
</brief_title>
<official_title>
<textblock>
  A Phase II Multicenter Uncontrolled Trial of BAY 43-9006 in Subjects With Metastatic Breast Cancer.
</textblock>
</official_title>
<study_sponsor>
<lead_sponsor>
<agency>
  Bayer
</agency>
</lead_sponsor>
</study_sponsor>
<resp_party>
<name_title>
  Therapeutic Area Head
</name_title>
<organization>
  Bayer Spa
</organization>
</resp_party>
<oversight_info>
<regulatory_authority>
  United States: Food and Drug Administration
</regulatory_authority>
<has_dmc>
  No
</has_dmc>
</oversight_info>
<brief_summary>
<textblock>
The  purpose  of  this  study  is  to  evaluate  the  anti-cancer  activity  and  safety  of  BAY  43-9006  (sorafenib)  in  patients,  who  suffer  from  an  advanced  breast  tumour, which  has  spread  to  other  organs  of  body  despite  treatment  that  the  patient  has  received  so  far.  
</textblock>
</brief_summary>
<detailed_descr>
<textblock>
</textblock>
</detailed_descr>
<status_block>
<status>
 Completed 
</status>
<date>
2008-10 
</date>
</status_block>
<start_date>
<date>
  2004-02
</date>
</start_date>
<end_date>
<date>
</date>
</end_date>
<last_follow_up_date
 type="Actual"
>
<date>
  2008-01
</date>
</last_follow_up_date>
<primary_compl_date
 type="Actual"
>
<date>
  2006-01
</date>
</primary_compl_date>
<phase_block>
<phase>
  Phase 2
</phase>
</phase_block>
<study_type>
  Interventional
</study_type>
<design>
  Treatment
</design>
<design>
  Non-Randomized
</design>
<design>
  Open Label
</design>
<design>
  Uncontrolled
</design>
<design>
  Single Group Assignment
</design>
<design>
  Safety/Efficacy Study
</design>
<number_of_arms>
  1
</number_of_arms>
<primary_outcome>
<measure>
  Best overall response rate, including CR and PR, of BAY 43-9006 as single agent in subjects with MBC as per Modified WHO Tumour Response Criteria
</measure>
<time_frame>
  Measured whenever it happens
</time_frame>
<safety_issue>
  No
</safety_issue>
</primary_outcome>
<secondary_outcome>
<measure>
The  time  to  disease  progression,  time  to  response,  duration  of  response  and  survival  time, The  rate  of  non-responders  with  SD  for  at  least  16  weeks, The  quantitative  and  qualitative  toxicity  of  BAY  43-9006  in  this  subject  population  based  on  NCI-CTCAE  
</measure>
<time_frame>
  Measured whenever it happens
</time_frame>
<safety_issue>
  Yes
</safety_issue>
</secondary_outcome>
<enrollment
 type="Actual"
>
  54
</enrollment>
<condition>
  Cancer
</condition>
<condition>
  Breast Cancer
</condition>
<arm_group>
<arm_group_label>
  Arm 1
</arm_group_label>
<arm_type>
  Experimental
</arm_type>
<description>
<textblock>
</textblock>
</description>
</arm_group>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  Nexavar (Sorafenib, BAY43-9006)
</primary_name>
<description>
<textblock>
  BAY 43-9006 400 mg b.i.d. daily
</textblock>
</description>
<arm_group_label>
  Arm 1
</arm_group_label>
</intervention>
<eligibility>
<criteria>
<textblock>
  Inclusion Criteria:
  - Age &gt; 18 years
  - Women with prior histologically documented diagnosis of breast cancer 
  - Subjects with metastatic disease who have already received and failed at least one chemotherapy regimen for metastatic disease and, if ER/PgR +ve, have failed on at least adjuvant hormonal therapy
  - Subjects for whom trastuzumab treatment is not indicated, no longer effective or refused by the subjects 
  - Four weeks since the last cytotoxic chemotherapy or clear evidence of progression on hormonal therapy 
  - Subjects who have at least one measurable lesion by CT scan or MRI according to modified WHO Tumour Response Criteria
  - Subjects who have an Eastern Co-operative Oncology Group (ECOG) performance status of 0, 1 or 2 
  - Adequate bone marrow, liver and renal function as assessed by the following laboratory evaluations: 
  - Hemoglobin &gt; 9.0 g/dl 
  - Absolute neutrophil count (ANC) &gt; 1,500/mm3 
  - Platelet count = 100,000/&#181;l 
-  Total  bilirubin    =1.5 x  the  upper  limit  of  normal. 
  - ALT and AST = 2.5 x upper limit of normal (=5 x upper limit of normal for subjects with liver involvement of their cancer)
  - Amylase and lipase = 1.5 x the upper limit of normal
  - Serum creatinine = 3.0 x the upper limit of normal
  - PT or INR and PTT &lt; 1.5 x upper limit of normal (subjects who receive anti-coagulation treatment with an agent such as warfarin or heparin will be allowed to participate provided that no evidence of underlying abnormality in these parameters exists)
  - Subjects who give written informed consent prior to any study specific screening procedures with the understanding that the subject has the right to withdraw from the study at any time, without prejudice
  - Life expectancy of at least 12 weeks
  - Signed informed consent must be obtained prior to any study specific procedures
  Exclusion Criteria:
  - Previous malignancy (except for cervical carcinoma in situ, adequately treated basal cell carcinoma, or superficial bladder tumours [Ta, Tis and T1] or other malignancies curatively treated &gt; 2 years prior to entry) 
  - Congestive heart failure &gt; NYHA Class II 
  - Cardiac arrhythmia requiring anti-arrhythmic (excluding beta blockers or digoxin) 
  - Active coronary artery disease or ischaemia 
  - Active clinically serious bacterial or fungal infections (&gt; grade 2 NCI-CTC, Version 3) 
  - Known History of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C 
  - Metastatic brain or meningeal tumors unless the subject is &gt; 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry. Also the patient must not be undergoing acute steroid therapy or taper (chronic steroid therapy is acceptable provided that the dose is stable for 1 month prior to and following screening radiographic study)
  - Subjects with seizure disorders requiring medication (such as steroid or anti-epileptics) 
  - History of organ allograft 
  - Substance abuse, medical, psychological or social conditions that may interfere with the subject&apos;s participation in the study or evaluation of the study results 
  - Known or suspected allergy to the investigational agent 
  - Any condition that is unstable or which could jeopardize the safety of the subject and his/her compliance in the study. Pregnant or breast-feeding subjects. Women of childbearing potential must have a negative pregnancy test performed within seven days prior to the start of study drug. Women enrolled in this trial must use adequate barrier birth control measures during the course of the trial.
 
  Excluded therapies include: 
  - Anti -cancer chemotherapy, hormonal therapy or immunotherapy during the study or within 4 weeks of study entry. Mytomicin or nitroureas should not be given within 6 weeks of study entry
  - Significant surgery within 4 weeks prior to the start of study drug
  - Any bone marrow transplant or stem cell rescue within 4 months of the start of study drug 
  -Radiotherapy during the study or within 3 weeks of the start of drug 
  - Use of biologic response modifiers, such as G-CSF, within 3 weeks of study entry 
  - Investigational drug therapy outside of this trial during or within 30 days prior to start of the study drug 
  - Concomitant treatment with ketoconazole, itraconazole, ritonavir, or use of grapefruit juice 
  -Prior use of Raf-kinase inhibitors (RKI), MEK or farnesyl transferase inhibitors 
  - Concomitant treatment or use of St. John&apos;s Wort 
  - Prior use of bevacizumab and all other drugs that target VEGF/VEGF receptors
</textblock>
</criteria>
<healthy_volunteers>
  No
</healthy_volunteers>
<gender>
  Female
</gender>
<minimum_age>
  18 Years
</minimum_age>
<maximum_age>
</maximum_age>
</eligibility>
<investigator>
<role>
  Study Director
</role>
<name>
  Bayer Study Director
</name>
<affiliation>
<agency>
  Bayer
</agency>
</affiliation>
</investigator>
<contact>
<name>
Bayer  Clinical  Trials Contact  
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
  clinical-trials-contact@bayerhealthcare.com
</email>
</contact>
<contact>
<name>
  For trial location information (Phone Menu Options &apos;3&apos; or &apos;4&apos;)
</name>
<phone>
  (+)1-888-84 22937
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
<location>
<facility>
<name>
</name>
<address>
<city>
  Stuttgart
</city>
<state>
  Baden-W&#252;rttemberg
</state>
<zip>
  70199
</zip>
<country>
  Germany
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
</name>
<address>
<city>
  M&#252;nchen
</city>
<state>
  Bayern
</state>
<zip>
  80637
</zip>
<country>
  Germany
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
</name>
<address>
<city>
 Frankfurt 
</city>
<state>
  Hessen
</state>
<zip>
  60596
</zip>
<country>
  Germany
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
</name>
<address>
<city>
  Milano
</city>
<state>
</state>
<zip>
  20133
</zip>
<country>
  Italy
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
</name>
<address>
<city>
  Milano
</city>
<state>
</state>
<zip>
  20162
</zip>
<country>
  Italy
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
</name>
<address>
<city>
  Bologna
</city>
<state>
</state>
<zip>
  40138
</zip>
<country>
  Italy
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
</name>
<address>
<city>
 Parma 
</city>
<state>
</state>
<zip>
  43100
</zip>
<country>
  Italy
</country>
</address>
</facility>
<status>
 Completed 
</status>
</location>
<see_also>
<annotation>
<textblock>
  Click here and search for drug information provided by the FDA
</textblock>
</annotation>
<url>
  http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm
</url>
</see_also>
<see_also>
<annotation>
<textblock>
  Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product
</textblock>
</annotation>
<url>
  http://www.fda.gov/medwatch/safety.htm
</url>
</see_also>
<see_also>
<annotation>
<textblock>
  Click here to find results for studies related to marketed products
</textblock>
</annotation>
<url>
  http://www.clinicalstudyresults.org
</url>
</see_also>
<initial_release_date>
  2005-01-10
</initial_release_date>
<last_release_date>
2008-10-21 
</last_release_date>
<init_results_release_date>
</init_results_release_date>
</clinical_study>
